Dr. Rubenstein has over 20 years of experience in management of biotechnology and medical equipment companies. Dr. Rubenstein is presently Clinical Professor of Neurology and Pediatrics at the NYU Langone Medical Center. He is the founder and the former CEO of NexGenix Pharmaceuticals Inc., a biotechnology company focused on drug development for neurofibromatosis and related sporadic tumors. He also serves as the Vice-Chairman and Lead Director of the Cooper Companies (COO, NYSE), a medical products company. Dr. Rubenstein was one of the founding members of the Children's Tumor Foundation and also founded the Mount Sinai Neurofibromatosis Research and Treatment Center. He has been recognized in Who's Who in the East and Who's Who in Science and Technology. He has provided counsel to numerous research and governmental agencies, including the NINDS, the Neurogenetics Study Section of the National Cancer Institute, and the Department of Defense NF Research Program. He is a reviewer for several scientific publications and was a Contributing Editor for the Mount Sinai Journal of Medicine for many years. Dr. Rubenstein graduated from Cornell University. His medical education began at the University of Rochester, School of Medicine, and was completed at the Tufts University School of Medicine in Boston. His Neurology specialty training was completed at the Columbia Presbyterian Medical Center- Neurological Institute in New York.
Dr. Prasad co-founded Plex in 2009. Since its incorporation he has been instrumental in raising nearly $3M, predominantly through non-dilutive mechanisms from multiple NIH SBIR grants and two major grants from the Michael J. Fox Foundation for Parkinson’s Research. Dr. Prasad has over 20 years of combined academic and industry experience in the field of structural biology and its application for the discovery of small molecule drug candidates. He was the lead crystallographer and core member of the team that discovered Nesina®, a drug for the treatment of type 2 diabetes, which was discovered using a structure-based method. He has been principal investigator on multiple NIH funded SBIR grants and a co-investigator on R21 exploratory grant. In addition, he was the program director for a multi-institutional Therapeutics Development Grant funded to Plex Pharmaceuticals by the Michael J. Fox Foundation for Parkinson’s Research. He serves as a reviewer on the NIH Special Emphasis Panel to evaluate Small Business (SBIR-STTR) grant applications. Prior to co-founding Plex, he held positions as Senior Scientific Investigator, Research Fellow and Associate Director at Metabasis Therapeutics, Merck and Co., and Syrrx respectively. Dr. Prasad obtained his PhD from the Indian Institute of Science, Bangalore, India and did his post-doctoral training at the University of Minnesota Medical School and the Scripps Research Institute, La Jolla, California.